Vasopeptidase inhibitors are a novel and effective strat- dase inhibitor, at both low dose and high dose, in re-
vention of atrial natriuretic peptide (ANP) degradation
Methods. STNx rats were randomized to four groups and of greater blood pressure reduction and cardiovascular
Results. Elevated blood pressure in STNx rats (174 Ϯ 9 benefits, with this issue under intensive investigation [2] . inhibitor increased urinary ANP and modulated natriCompared with fosinopril, omapatrilat treatment was associuresis without improving blood pressure or protein exated with increased plasma renin activity and decreased renal ACE and NEP binding in a dose-dependent manner.
cretion [8, 9] . However, CGS 30440, a dual ACE/NEP Conclusion. These findings suggest that vasopeptidase inhivasopeptidase inhibitor, conferred greater reduction in bition may provide a useful strategy for the treatment of proproteinuria than benazepril, an ACE inhibitor, despite gressive renal disease. similar effects on blood pressure [10] . At both low dose and high dose, CGP 30440 achieved a similar reduction in blood pressure and proteinuria over a period of six weeks [10] . Whether further lowering blood pressure with a vasopeptidase inhibitor could further ameliorate proteinuria in this model of progressive renal injury remains 1 Current address: Department of Medicine, University of Melbourne, unexplored. Furthermore, the effect of vasopeptidase
METHODS

Kidney histopathology
Assessment of glomerulosclerosis and tubulointerstiExperimental protocol tial injury was performed as described previously [7, 15] . Experimental procedures were in accordance with the In brief, 30 glomeruli in each kidney were graded from National Health and Medical Research Council of Aus-0 to 4 according to the severity of the glomerular sclerotralia guidelines for animal experimentation. STNx (N ϭ sis: 0 ϭ normal; 1 ϭ slight glomerular damage, the mesan-48) or sham surgery (control, N ϭ 12) was performed gial matrix and/or hyalinosis with focal adhesion, involvin eight-week-old male Sprague-Dawley rats (body ing Ͻ25% of the glomerulus; 2 ϭ sclerosis of 25 to 50%; weight of 220 to 310 g) as described previously [6, 7] . In 3 ϭ sclerosis of 50 to 75%; and 4 ϭ sclerosis of Ͼ75% of brief, the STNx was performed by right nephrectomy, the glomerulus [7, 15] . Twenty fields of tubulointerstitial followed by infarction of approximately two thirds of the area in the cortex were observed and graded as follows: left kidney with selective ligation of all but one extrarenal 0 ϭ normal; 1 ϭ the area of interstitial inflammation and branch of the left renal artery. Anesthesia was achieved fibrosis, tubular atrophy, and dilation, with cast formation by intraperitoneal injection of pentobarbitone sodium involving Ͻ25% of the field; 2 ϭ lesion area between (60 mg/kg body weight; Boehringer Ingelheim, Artar-25 and 50% of the field; and 3 ϭ lesions involving Ͼ50% mon, NSW, Australia). Following subtotal nephrectomy, of the field [7, 15] . Indices of glomerular damage or the animals were randomly allocated to an untreated group tubulointerestitial lesion were calculated by averaging (STNx, N ϭ 14) or the treatment with either a vasopeptithe grades assigned to all glomeruli, or tubular fields. dase inhibitor or an ACE inhibitor for 12 weeks. The
The data were expressed relative to the control group. vasopeptidase inhibitor omapatrilat (Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, USA)
In vitro autoradiography for renal ACE and NEP was administered by daily gavage at a low dose of 10
Angiotensin-converting enzyme and NEP binding in mg/kg/day (omapatrilat low dose, N ϭ 12) or at a high the kidney (N ϭ 5 per group) were assessed using in dose of 40 mg/kg/day (omapatrilat high dose, N ϭ 10).
vitro quantitative autoradiography as previously deThe ACE inhibitor fosinopril (Bristol-Myers Squibb scribed [16] [17] [18] . The rat kidneys (N ϭ 5, per group) were Pharmaceutical Research Institute) was administered at obtained after the animals were anesthetized with an a dose of 10 mg/kg/day by gavage (fosinopril, N ϭ 12).
intravenous injection of pentobarbitone sodium (60 mg/ The rats had unrestricted access to water and standard kg). The kidneys were removed, bisected, and snap frorat chow. Systolic blood pressure (SBP) was measured zen in liquid nitrogen-cooled isopentane and stored at by indirect tail-cuff plethysmography in prewarmed un-Ϫ20ЊC. Twenty-micron sections were cut on a cryostat anesthetized animals as previously described [11], every at Ϫ20ЊC and then dehydrated overnight under reduced four weeks after surgery. At the end of the experiment, pressure at 4ЊC. animals were anesthetized by intraperitoneal injection
The sections were preincubated for 15 minutes in 10 of pentobarbitone sodium (60 mg/kg body weight). A mmol/L sodium phosphate buffer (pH 7.4). For renal midline incision of the abdomen was made, and the rem-ACE binding, sections were incubated in a fresh volume nant kidney was removed and weighed. A portion of of the same buffer containing selective ligand for ACE, kidney was fixed in 10% formalin and embedded with 125 I-MK351A (a tyrosyl derivative of enalaprilic acid) paraffin with standard procedure. Four-micron paraffin [19] , at room temperature for two hours. For renal NEP sections of kidney were used for histopathology. Another binding, sections were incubated with same buffer conportion of the kidney was frozen in liquid nitrogen and taining selective ligand for NEP,
Assessment of renal function
room temperature for two hours [20] . After incubation, Glomerular filtration rate (GFR) was measured using the sections were washed four times for one minute each the 99m Tc-DTPA method at the conclusion of the experiin ice-cold buffer and were air dried at room temperament [12] . Prior to sacrifice, animals were housed in ture. All slides, including a set of radioactivity standards, metabolic cages for 24 hours for collection of urinary were exposed to Kodak BioMax x-ray film at room temsamples and measurement of urinary protein excretion perature for five days [9] . Following exposure, the films using the Coomassie Brilliant Blue Method [13] . Plasma were processed and the optical densities quantitated by urea and creatinine concentrations were measured by a microcomputer imaging device (MCID Imaging Sysautoanalyzer (Beckman Instruments, Palo Alto, CA, tem, St. Catherines, Ontario, Canada) connected to an USA). Blood samples were collected from the tail vein IBM AT computer. The computer program using the of conscious rats before the animals were sacrificed for radioactivity standards constructed a calibration curve of optical density versus radioactivity density. Specific the measurement of plasma renin activity (PRA) [14] . 
Statistical analysis
Data were analyzed by analysis of variance (ANOVA) using the Statview SE program (Brainpower, Calabasas, CA, USA) on a Macintosh iMac Computer (Cupertino, CA, USA). Comparisons of group means were performed by Fisher's least significant difference method. Data are shown as mean Ϯ SEM unless otherwise specified. PRA data were analyzed after logarithmic transformation. A P value of less than 0.05 was viewed as statistically significant. of kidney:body weight were increased in untreated STNx rats compared with control rats. Rats treated with the vasopeptidase inhibitor omapatrilat tended to have a mean blood pressure by approximately 25 mm Hg, less lower kidney weight and kidney:body weight ratio, but than that achieved with low-dose omapatrilat. omapatrilat only at the high dose was associated with Plasma renin activity reduced kidney weight and kidney:body weight ratio Subtotally nephrectomized rats were associated with (Table 1) .
RESULTS
Body weight and kidney weight
reduced PRA when compared with control animals (Table 1). The administration of omapatrilat was associated Systolic blood pressure with increased PRA in a dose-dependent manner, with Serial SBP values at weeks 4, 8, and 12 after surgery the level in the lower dose being similar to and in the are shown in Figure 1 , and the mean values of these high dose being higher than that observed in sham animeasurements are calculated (Table 1) . SBP was elevated mals (Table 1) . PRA was increased by treatment with in untreated STNx rats. The vasopeptidase inhibitor omafosinopril to similar levels as observed in sham rats or patrilat ameliorated the rise in SBP in a dose-dependent STNx rats treated with the lower dose of omapatrilat manner. Rats treated with low-dose omapatrilat had sim- (Table 1) . ilar blood pressure to that observed in control rats. Rats
Urinary protein excretion treated with high-dose omapatrilat had lower blood pressure than rats treated with omapatrilat at low dose or Urinary protein excretion was significantly increased in STNx rats (median 258 mg/day, range 106 to 637 mg/ the control group. The ACE inhibitor fosinopril reduced Table 2 ). Treatment with omapatrilat was associated with reduction in proteinuria in a dose-dependent manner (low-dose median 26 mg/ day, range 9 to 55 mg/day; high-dose median 18, range 7 to 34 mg/day), with the lower dose vasopeptidase inhibitor being associated with levels of proteinuria similar to that seen in sham animals ( Table 2 ). Proteinuria was reduced in fosinopril-treated rats (median 71mg/day, range 19 to 242 mg/day), but to a level that was still higher than in control or STNx animals treated with either dose of omapatrilat (Table 2) .
GFR, plasma urea, and creatinine clearance
Subtotally nephrectomized rats had decreased GFR and increased plasma urea and creatinine levels when compared with control animals ( Table 2 ). These parameters were reduced to similar levels with all treatments and were still higher than that observed in control animals (Table 2 ). There were no significant differences in GRF among STNx rats treated with either omapatrilat or fosinopril (Table 2) .
Kidney histology
Subtotally nephrectomized rats developed glomerulosclerosis ( Fig. 2A ) and tubulointerstitial fibrosis (Fig. 2B ) compared with control animals. Both omapatrilat and fosinopril reduced glomerulosclerosis and tubulointerstitial fibrosis to a similar extent.
In vitro autoradiography for renal ACE and NEP
In kidneys of control rats, ACE (Fig. 3A) and NEP with control rats where renal ACE trended to elevation compared with control, but did not reach significance DISCUSSION (Table 3 and Fig. 3 ). Treatment with omapatrilat causes a dose-dependent inhibition of renal NEP and ACE The present study demonstrates the beneficial effects of binding. ACE binding was reduced by omapatrilat in a long-term administration of omapatrilat, in a dose-dependose-dependent manner compared with untreated STNx dent manner, on reducing blood pressure and proteinuria and retarding glomerulosclerosis and tubulointerstitial rats and to a greater extent than fosinopril (Table 3) . Since omapatrilat reduced proteinuria in a dose-depena P Ͻ 0.05 vs. control, b P Ͻ 0.01 vs. STNx, c P Ͻ 0.01 vs. fosinopril dent manner in an association with reduction in blood d P Ͻ 0.01 vs. low-dose omapatrilat pressure, its effect on proteinuria may be entirely pressure related. Indeed, it has been demonstrated that with similar blood pressure reduction, blockade of the RAS fibrosis in progressive renal injury. In the present study, with either an ACE inhibitor or an angiotensin type 1 the beneficial effects of omapatrilat were associated with (AT1) receptor antagonist conferred a similar degree of a concomitant inhibition of renal ACE and NEP activity, renoprotection [5] . This issue has been further explored as assessed by quantitative autoradiography with specific by using accurate radiotelemetric assessment of blood ligands for these vasoactive enzymes. These findings expressure in the subtotal nephrectomy model [24] . These tend the results of previous studies showing beneficial studies also showed the pressure-dependent nature of effects of vasopeptidase inhibitor in ameliorating renal the benefits conferred by RAS blockers [24] , as has a injury [10] , and suggest that vasopeptidase inhibition recent study by our group in which a combination of an may be a therapeutic approach for retarding progression of renal injury in which reducing both blood pressure ACE inhibitor and an AT1 receptor antagonist conferred a greater reduction in proteinuria and blood pressure ment of proteinuria and renal structural injury. Such a possibility has been recently suggested from studies using than single agent therapy [7] . a neutralizing antibody to transforming growth factor-␤ Treatment with the vasopeptidase inhibitor was asso- [25] . This treatment in a model of diabetic nephropathy ciated with preservation of renal function, as assessed was associated with a reduction in renal fibrosis, yet no by improved GFR and lower plasma urea and creatinine effects on albuminuria [25] . concentrations compared with untreated STNx rats. The Tissue ACE measurements have been used previously effects of vasopeptidase inhibition on renal function were, as a marker of the degree of inhibition of local ACE however, similar to that achieved with an ACE inhibitor. activity in various organs including the kidney [26] . ReAlthough administration of either a vasopeptidase inhibduced kidney ACE binding has been demonstrated after itor or an ACE inhibitor had no influence on weight gain, administration of various ACE inhibitors and was shown vasopeptidase inhibitor-treated rats had reduced kidney to correlate with the hypotensive efficacy of the drugs weight and kidney to body weight ratio compared with [27] . Compared with untreated rats, both fosinopril and the ACE inhibitor-treated rats. The mechanisms underomapatrilat inhibited renal ACE binding with the degree lying these differences in kidney weight are uncertain.
of inhibition correlating with their hypotensive effects. Since vasopeptidase inhibitor or ACE inhibitor-treated
In the present study, an increase in PRA was seen with rats gained similar weight over the period of experiment, both drugs, particularly with a high dose of omapatrilat. a lower kidney weight and a subsequent lower kidney/ These findings are consistent with a recent study showing body weight ratio in vasopeptidase inhibitor-treated animore potent effects of omapatrilat compared with fosimals may represent a specific antitrophic effect of this nopril in inhibiting angiotensin I hydrolysis [28] . agent, which warrants further examination.
Although kidney NEP activity was mildly decreased Vasopeptidase inhibitor therapy was associated with simin untreated rats compared with control rats, omapatrilat ilar amelioration of glomerulosclerosis and tubulointeralso inhibited renal NEP activity in a dose-dependent stitial fibrosis, as obtained by the ACE inhibitor alone, manner, suggesting that NEP inhibition, as an additional even though vasopeptidase inhibition conferred greater factor, may have contributed to its efficacy as a hypotenhypotensive effects. Furthermore, the effect of omapatrilat sive agent and in conferring renoprotection. Compared on renal pathology was not further enhanced at a higher with the fosinopril, the vasopeptidase inhibitor omapatridose. These findings are consistent with previous obserlat was associated with greater inhibition on both renal vations, which showed a similar relationship between blood ACE and NEP and increased PRA. These findings sugpressure reduction conferred by the RAS blockers and gest that the superiority in reducing blood pressure and amelioration of renal pathological injury in this model proteinuria with vasopeptidase inhibition involves not [7] . Specifically, we observed in that study that greater only NEP inhibition, but also ACE inhibition. hypotensive and antiproteinuric efficacy of combined ACE inhibition and AT1 receptor blockade was not asso-ACKNOWLEDGMENTS ciated with a further improvement in renal pathology [7] . ity is that although blood pressure is a major determent of injury in this model, other factors such as the renal APPENDIX response to renal mass reduction are not influenced by blood pressure reduction and, therefore, cannot be toAbbreviations used in this article are: ACE, angiotensin-converting enzyme; ANP, atrial natriuretic peptide; AT1, angiotensin II type 1; tally abrogated by this form of treatment. Finally, one GFR, glomerular filtration rate; NEP, neutral endopeptidase; PRA, cannot exclude subtle differences in these treatments on plasma renin activity; RAS, renin-angiotensin system; SBP, systolic renal morphological abnormalities that would require blood pressure; STNx, subtotally nephrectomized. more sophisticated assessment of glomerular and tubulointerstitial ultrastructure. The difference in drug effects REFERENCES on proteinuria and renal structure may indicate that vari-1. Fournie-Zaluski MC, Coric P, Turcaud S, et al: New dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme:
ous pathological pathways are involved in the develop-
